Form 8-K - Current report:
SEC Accession No. 0001193125-25-118839
Filing Date
2025-05-13
Accepted
2025-05-13 16:19:40
Documents
15
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d88474d8k.htm   iXBRL 8-K 25897
2 EX-99.1 d88474dex991.htm EX-99.1 76591
6 GRAPHIC g88474g0514002116983.jpg GRAPHIC 3524
  Complete submission text file 0001193125-25-118839.txt   241347

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrca-20250513.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrca-20250513_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrca-20250513_pre.xml EX-101.PRE 11262
17 EXTRACTED XBRL INSTANCE DOCUMENT d88474d8k_htm.xml XML 3613
Mailing Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380
Business Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380 484-453-3300
Verrica Pharmaceuticals Inc. (Filer) CIK: 0001660334 (see all company filings)

EIN.: 463137900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38529 | Film No.: 25940421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)